Efficacy of Cough and Cold OTC Drugs in Pediatric Populations Wayne R. Snodgrass, M.D., Ph.D. University of Texas Medical Branch October 18, 2007.

Slides:



Advertisements
Similar presentations
Does the use of antipyretics in children prolong febrile illness? David King Clinical Research Fellow 05/09/2013.
Advertisements

Metoclopramide versus Hydromorphone for the ED Treatment of Migraine Headaches Justin Griffith, MD Mark Mycyk, MD Demetrios Kyriacou, MD, PhD ICEP Resident.
Evidence-Based Medicaid: Health Care That Works Pay for Performance: Health Care That Adds Value Jeff Thompson MD MPH Chief Medical Officer Washington.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 77 Drugs for Allergic Rhinitis, Cough, and Colds.
Great Ormond Street Hospital for Children NHS Trust The School of Pharmacy UCL INSTITUTE OF CHILD HEALTH Centre for Paediatric Pharmacy Research Drug Development.
Paul IM, Beiler JS, Vallati JR, Duda LM, King TS
Influenza Prevention We anticipate that there will be two types of influenza illness and two different types of influenza vaccine this year Seasonal influenza.
Difficulties in showing a dose- response with locally-acting nasal sprays and aerosols for allergic rhinitis Badrul A. Chowdhury, MD, PhD Medical Team.
 People to people contact through coughing and sneezing  May contract by touching something infected and touching it to the mouth or nose.
1 Efficacy and Safety of 3 Different IV Doses of Palonosetron for the Prevention of PONV in the Outpatient (Study 1) and Inpatient (Study 2) Settings Study.
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
NDAC December 14, Clinical Endpoints for Nasal Decongestants Xu Wang, M.D., Ph.D. Medical Officer Division of Pulmonary and Allergy Products Nonprescription.
OPTIMISING MEDICINES USE GRAHAM DAVIES Professor of Clinical Pharmacy & Therapeutics Institute of Pharmaceutical Science King’s College London.
NUTR 439: Communications in Dietetics May 18 th, 2009 Sarah Hallaj.
Introduction The purpose of this presentation is to encourage the NDAC to: Endorse (once again) the use of a dosing schedule based on the more finely divided.
SORE THROAT & OTITIS MEDIA
Joint NDAC/PAC meeting October 18, 2007 OTC Cold and Cough Products: Use in Children Advisory Committee Meeting October 18, 2007 Joel Schiffenbauer, MD.
1 One Year Post-Exclusivity Adverse Event Review: Ertapenem Pediatric Advisory Committee Meeting November 16, 2006 Alan M. Shapiro, MD, PhD, FAAP Medical.
Chickenpox in Children, Adults and Pregnancy: What to do?
The Risks of Cough/Cold Preparations to Young Children Michael Shannon, MD, MPH Children’s Hospital Boston Harvard Medical School.
Difficulties in showing a dose- response with locally-acting nasal sprays and aerosols for allergic rhinitis Badrul A. Chowdhury, MD, PhD Medical Team.
1 Informative Studies of New Therapeutic Agents in Major Depression, GAD & Panic W Z Potter, M.D., PhD. Merck Research Laboratories.
Rapivab™ - peramivir injection
ATLAS Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for Thrombosis and.
A Clinician’s Perspective on OTC Cough and Cold Products Daniel Levy, M.D., F.A.A.P. President, Maryland Chapter American Academy of Pediatrics.
Continuity Clinic Depression. Continuity Clinic Objectives.
Regulatory Experience Employing Extrapolation In Pediatric Drug Development William Rodriguez, M.D. Science Director of Pediatrics Office of Counter-Terrorism.
1 UPDATES BPCA - Enacted January 4, 2002 Pediatric Rule - In effect Pediatric Rule Statistics Exclusivity Statistics Reorganization.
Over the Counter Medication :. Overview of OTC Medications (Harris Survey) > 100,000 OTC Products Few unique active ingredients > 700 are former Rx meds.
CLAIMS STRUCTURE FOR SLE Jeffrey Siegel, M.D. Arthritis Advisory Committee September 29, 2003.
POTENTIATING THE IMMUNE SYSTEM IN CHILDREN: bringing up a better future through Ayurveda Abhimanyu Kumar MD(Ay), MSc(Psy),PhD
1 One Year Post Exclusivity Adverse Event Review: Fexofenadine Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004.
1 Proton-Pump Inhibitor (PPI) Template for Pediatric Written Requests Pediatric Advisory Subcommittee of the Anti- Infective Drug Advisory Committee Hugo.
Cardiovascular Drugs That Prolong The QT Interval
1 Vaccines and Related Biologic Products Advisory Committee (VRBPAC) May 16, 2007 FluMist ® Influenza Virus Vaccine Live, Intranasal Safety and Effectiveness.
History of Pediatric Labeling
PO 2726; IAS; Vicriviroc (formerly SCH ): Antiviral Activity of a Potent New CCR5 Receptor Antagonist D. Schuermann, C. Pechardscheck, R. Rouzier,
Sertraline Use in Pediatric Population: A Risk Benefit Discussion Steven J. Romano, MD September 13, 2004 Steven J. Romano, MD September 13, 2004 Joint.
CLINICAL EFFICACY TESTING for NASAL DRUGS Mary M. Fanning, M.D., Ph.D. Associate Director for Medical Affairs Office of Generic Drugs, FDA June 4, 1999.
1 Study Design Issues and Considerations in HUS Trials Yan Wang, Ph.D. Statistical Reviewer Division of Biometrics IV OB/OTS/CDER/FDA April 12, 2007.
Head-to-Head Comparison of Obinutuzumab (GA101) plus Chlorambucil (Clb) versus Rituximab plus Clb in Patients with Chronic Lymphocytic Leukemia (CLL) and.
Smallpox vaccine in combination with ST-246 Robert Jordan, Ph.D. SIGA Technologies, Inc FDA – Public HearingMay 17, 2007.
COMET: Carvedilol Or Metoprolol European Trial Purpose To compare the effects of carvedilol (a β 1 -, β 2 - and α 1 -receptor blocker) and short-acting.
Journal of the American Medical Association (JAMA), 2004, 291:
Locatelli F et al. Proc ASH 2013;Abstract 4378.
Systemic Exposure of Topical Tacrolimus Veneeta Tandon, Ph.D. Pharmacokinetics Reviewer Division of Pharmaceutical Evaluation III Office of Clinical Pharmacology.
Over-the-Counter Cough and Cold Product Medication Errors (in children under six years of age) Joint Meeting of the Nonprescription Drugs Advisory Committee.
1 One Year Post Exclusivity Adverse Event Review: Sumatriptan Pediatric Advisory Committee Meeting November 18, 2005 Susan McCune, M.D. Medical Officer.
Initiatives Drive Pediatric Drug Development January 30, 2002.
1 Robert J. Spiegel, M.D. Sr. V. P. Medical Affairs Chief Medical Officer Schering Plough FDA ADVISORY COMMITTEE 5/11/01.
Scientific Basis for Review of Varicella Zoster Immune Globulin Products Blood Products Advisory Committee July 21, 2005 Dorothy Scott, M.D. OBRR/CBER.
Tuberculosis in Children and Young Adults
1/11/01 Pediatric trials for ARV experienced children Coleen K. Cunningham Epidemiology of treatment experience in pediatrics How does the smaller number.
Food and Drug Administration Division of Pulmonary and Allergy Drug Products Summary Comments - Orally Inhaled and Intranasal Budesonide and Fluticasone.
ASENT/ISCTM, Feb 23 rd, 2012, Washington DC, USA Pharmaceuticals & Medical Devices Agency Pediatric Drug Development for Neuro-Psychiatric Diseases Yoshiaki.
Joint Non-Prescription Drugs and Pediatric Advisory Committee Meeting October 18-19, 2007 Considerations for Extrapolation of Efficacy from Adults to Children.
+ Legislative Advocacy: Why OTCs Go Over Parents’ Heads Allison Baxterbeck Elizabeth Chang Amy DiPilato.
The SYMPHONY Trial Reference Reddan DN, et al. Renal function, concomitant medication use and outcomes following acute coronary syndromes. Nephrol Dial.
Viagra (sildenafil citrate): Extensive Clinical and Post-Marketing Experience Michael Sweeney, MD Senior Medical Director Pfizer Inc.
© 2016 Direct One Communications, Inc. All rights reserved. 1 Recent Research Expands Our Understanding of Perampanel Christian M. Cabrera Kang, MD Emory.
Journal Club Neuropsychological effects of levetiracetam and carbamazepine in children with focal epilepsy. Rebecca Luke 2/9/2016.
Albert Z. Holloway MD, FAAP
Eucrisa™ - Crisaborole
Martha Carvour, MD, PhD March 2, 2017
Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study  Eli O. Meltzer, MD, Paul.
Issues in Hypothesis Testing in the Context of Extrapolation
Insomnia pharmacotherapy: Off-label antipsychotics
Obsessive-Compulsive Disorder: Pharmacotherapy
Between-night treatment effects of VR, petrolatum, and no treatment on (A) cough frequency (P = .003, 3-way treatment comparison), (B) cough severity (P.
Pediatric Drug Development A Regulatory Perspective
Presentation transcript:

Efficacy of Cough and Cold OTC Drugs in Pediatric Populations Wayne R. Snodgrass, M.D., Ph.D. University of Texas Medical Branch October 18, 2007

Overview I.Clinical Evidence of Efficacy - Brompheniramine - Chlorpheniramine - Dextromethorphan II.Risks of Extrapolation III. Adverse Effects IV. Rational Therapeutics

Clinical Evidence No more effective than placebo in relief of cough and cold symptoms in children BromopheniramineDiphenhydramine ChlorpheniramineGuaifenesin ClemastinePhenylephrine CodeinePhenylpropanolamine DextromethorphanSalbutamol

Brompheniramine Prospective, randomized, double-blind, placebo- controlled 7-point Likert scale, sx improvement 2h after dose N=59, age range 6 mo – 6 yrs SymptomDrugPlacebo Runny Nose (%) Nasal Congestion (%) Cough (%) Asleep (%) Clemens et al. J Pediatr 1997;130:

Chlorpheniramine Prospective, randomized, double-blind, placebo- controlled Symptom improvement at 3 days, rating scale: -1 (worse) to +3 (improved), pre-rx minus post-rx N = 143; age 1.5 mo to 5 yrs Symptom (%)PlaceboDrug Nasal Discharge Cough Slight drowsiness Sleepiness Sakchainanont B et al. J Med Assoc Thai (2):96-101

Dextromethorphan Single dose study; 30 minutes before bed 7-point Likert scale (0 to 6) N = 100; ages years SymptomDPHDMPlacebo Cough frequency222 Cough bother child Cough severity2.1 Parent’s sleep Combination symptom score910 Paul et al. Pediatrics 2004;114(1):e85-e90

Extrapolation Risks Pediatric research conducted under BPCA* has led to 133 labeling changes as of 8/07 Drugs previously approved for adults have been found to be: –Ineffective: Sumatriptan for migraines, Tolterodine for bladder incontinence –Incorrectly dosed: Gabapentin for partial seizures, Benazepril for pediatric hypertension *Best Pharmaceuticals for Children Act

Extrapolation Risks Many PK parameters change with developmental stage Sotalol PK Parameters Below 0.33 m 2 SA Acts as  -blocker More frequent QT prolongation Above 0.33 m 2 SAActs as K-channel blocker Increased plasma clearance and Vd

Extrapolation Risks Extrapolation also applies to clinical scenarios –Children have unpredictable clinical responses (fluoxetine, fluvoxamine trials) –Symptoms in a child may predict a different spectrum of disease than identical symptoms in an adult

Adverse Effects Numerous examples have revealed adverse effects unique to a pediatric population –Isotretinoin (Accutane) : increased bone demineralization –Topical pimecrolimus (Elidel) : increased infections, fever, and diarrhea –Propofol : increased mortality in multi-day continuous infusion

Next Steps: Rational Therapeutics Research on pathophysiology of the common cold: cytokines, chemokines, receptors Nasal spray vaccines and anti-viral drugs targeting rhinoviruses, parainfluenza ICAM-1 receptor antagonists